Factors associated with performance on the medicaid hedis measure: Continuity of antipsychotic (AP) medications for treatment of schizophrenia

Lafeuille, Marie-Hélène; Frois, Christian; Cloutier, Michel; Duh, Mei Sheng; Lefèbvre, Patrick; Pesa, Jacqueline; Clancy, Zoe; Fastenau, John; Durkin, Mike

doi:10.1016/j.jval.2014.03.1277

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study indicated Hispanics had greater adherence to paliperidone palmitate (1-month LAI) compared with other antipsychotics. 37 However, the study mixed oral and other LAI antipsychotics into one group, thereby limiting the results as oral and LAI agents may carry different adherence rates.…”

Section: Discussionmentioning

confidence: 99%

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data

Caballero,

Xu,

Hall

et al. 2023

Mental Health Clinician

View full text Add to dashboard Cite

Introduction In general, racial and ethnic differences exist in antipsychotic prescription practices. However, little is known about such differences between individual long-acting injectable (LAI) antipsychotic formulations, specifically. This study's primary objective was to determine racial and ethnic differences among LAI antipsychotic use. Secondary objectives were to identify if discontinuation rates differed between agents and by race or ethnicity. Methods International Classification of Diseases, 10th edition (ICD-10) codes were used to identify patients with schizophrenia and related disorders (18-64 years) who received an LAI antipsychotic between 2016 and 2020 using Merative Multi-State Medicaid databases. Using National Drug Code numbers for LAI antipsychotics, pharmacy claims were identified and data analyzed. Cochran-Mantel-Haenszel tests and odds ratio estimators were used to investigate conditional association between race or ethnicity and medication, while controlling for age, sex, health plan, and prescription year. Kaplan-Meier survival curves were examined, and stratified log-rank tests were conducted to compare the time until discontinuation distributions by race or ethnicity. Results The analysis included 37 712 patients. Blacks received an LAI first-generation antipsychotic more often than Whites (OR: 1.64, 95% CI: [1.56, 1.73], Hispanics (OR: 1.46, 95% CI: [1.21, 1.75]) and others (OR: 1.44, 95% CI: [1.20, 1.73]). Aside from fluphenazine decanoate showing earlier discontinuation rates for Whites over Blacks (P = .02), no significant differences in discontinuation across race or ethnicity were identified. Discussion Despite no significant differences in second-generation antipsychotic LAI discontinuation rates between Blacks and other racial or ethnic groups, Blacks received second-generation antipsychotic LAIs significantly less often than other groups. Further studies are needed to determine why differences may be occurring.

show abstract

Section: Discussionmentioning

confidence: 99%

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data

Caballero,

Xu,

Hall

et al. 2023

Mental Health Clinician

View full text Add to dashboard Cite

show abstract

“…1 Despite the need for continuous drugs treatment, medication compliance remains a critical issue in schizophrenia, with non-adherence rates ranging from 34% to 81%. [2][3][4][5][6][7][8] Antipsychotics non-adherence leads to a greater risk of relapses and negative overall outcomes. 9,10 Several factors, such as lack of insight, comorbid disorders (substances use and depressive symptoms), side effects, cognitive impairment and high hostility levels, can play a role in medication nonadherence in schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs

Bramante¹,

Salvo²,

Maina³

et al. 2023

NDT

View full text Add to dashboard Cite

International guidelines suggest long-term antipsychotic therapies for treating schizophrenia; however, medication compliance remains a critical issue in schizophrenia. Paliperidone palmitate (PP) is a second-generation antipsychotic long-acting injectable (SGA-LAI) approved for the treatment of schizophrenia. To date, the majority of studies on PP compliance patterns did not use specific instruments to assess medications' adherence, have been performed in not naturalistic samples and present partially overlapping populations. We conducted a systematic review in which we aimed to review the current knowledge on PP-LAI adherence levels and to describe healthcare resource utilisation and costs related to PP-LAI treatment. The evaluation has been conducted by searching in different databases (PubMed, Ovid, Scopus, and Cochrane Library) from inception to September 2022. Our findings suggest that paliperidone palmitate should be considered a good treatment strategy for patients affected by schizophrenia: PP showed both a good efficacy and tolerability and better adherence patterns and more favourable healthcare resource utilisation and costs, compared to OA.

show abstract

“…Psychotic symptoms usually respond to antipsychotic medications, which are also used for long-term maintenance and prevention (Kane and Correll, 2019). Yet, according to research, due to a multitude of factors, 34–81% of patients discontinue their antipsychotic medications with many studies putting the rate around 50% (Yang et al, 2012; El-Mallakh and Findlay, 2015; García et al, 2016; Lafeuille et al, 2016; Bright, 2017; De Las Cuevas et al, 2017; Velligan et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Adherence of patients with schizophrenia to hypothyroidism treatment

Gur,

Weizman,

Hermesh

et al. 2023

Camb. prisms Glob. ment. health

View full text Add to dashboard Cite

Adherence to prescription medications is critical for both remission from schizophrenia and control of physical comorbidities. While schizophrenia with comorbid hypothyroidism is common, there is little research on adherence to hypothyroidism treatment in this population. The current study used a retrospective, matched case-control design. The cohort included 1,252 patients diagnosed with schizophrenia according to ICD-10 and 3,756 controls matched for gender, age, socioeconomic status and ethnicity without diagnosis of schizophrenia. All data were retrieved from the electronic medical database of a large health maintenance organization. Retrieved data included demographics, thyroid functionality test results and prescribed medications. Measures of adherence to therapy were used for analyses as were data from follow-ups of patients with hypothyroidism. A diagnosis of hypothyroidism was found in 299 patients, 115 of whom were also diagnosed with schizophrenia. The 184 without schizophrenia constituted the control group. No statistically significant differences were found between the two groups regarding prescriptions for L-thyroxin and TSH levels and number of TSH tests. Adherence of patients with schizophrenia to hypothyroidism treatment was found to be as good as that of individuals without a schizophrenia diagnosis.

show abstract

Factors associated with performance on the medicaid hedis measure: Continuity of antipsychotic (AP) medications for treatment of schizophrenia

Cited by 3 publications

References 0 publications

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data

Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs

Adherence of patients with schizophrenia to hypothyroidism treatment

Contact Info

Product

Resources

About